文献速递骨软组织肉瘤与黑色素瘤

基因组分级指数可预测软组织肉瘤术后临床结局

The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma.
PubMed 文献 · Ann Oncol · 2018-01-01

该研究基于678例手术切除的软组织肉瘤(STS)的基因表达与临床病理数据,评估乳腺癌来源的108基因特征基因组分级指数(GGI)的预后价值。GGI-high组较GGI-low组5年无转移生存(MFS)更差(53% vs 78%,P=3.02E-11),转移复发风险比为2.92(95%CI 2.10-4.07;P=2.23E-10)。多变量分析中GGI分类保持独立预后价值,而病理分级不再显著。

要点

  • GGI将678例STS分为GGI-low 275例(41%)与GGI-high 403例(59%)。
  • GGI-high组5年MFS为53%(95%CI 47-59),低于GGI-low组的78%(95%CI 72-85)。
  • 多变量分析中GGI分类独立显著,病理分级不显著。

核心结论

  • GGI可细化手术切除STS患者的MFS预测,并可能改善辅助化疗的个体化选择。
  • 需在更大样本的回顾性及前瞻性系列中进一步临床验证,并对相关基因进行功能验证以探索新治疗靶点。

研究设计与样本

  • 收集678例手术切除STS的基因表达与临床病理数据,分析GGI分类与临床病理变量(含MFS)的相关性。

主要发现

  • GGI-high组较GGI-low组更常伴不良预后特征:病理3级(P=9.50E-11)、未分化肉瘤和平滑肌肉瘤(P<1.00E-06)、四肢部位(P<1.00E-06)、复杂遗传学特征(P=2.1E-20)。
  • GGI-high组5年MFS为53%(95%CI 47-59),GGI-low组为78%(95%CI 72-85),P=3.02E-11;转移复发风险比HR 2.92(95%CI 2.10-4.07;P=2.23E-10)。
  • 多变量分析中GGI分类保持显著,病理分级不显著;GGI分类可将病理1-2级和病理3级患者分别再分为5年MFS不同的两类。
  • GGI与CINSARC多基因特征与临床病理变量的相关性相似,但GGI更强;低/高危分类一致率为71%;多变量分析中两者对MFS均有独立预后价值,提示预后信息互补。

临床怎么用

  • GGI可细化手术切除STS的MFS预测。
  • GGI可能改善辅助化疗的个体化选择。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Soft-tissue sarcomas (STSs) are a group of rare, heterogeneous, and aggressive tumors, with high metastatic risk and relatively few efficient systemic therapies. We hypothesized that the Genomic Grade Index (GGI), a 108-gene signature previously developed in early-stage breast cancer, might improve the prognostic assessment of patients with early-stage STS. PATIENTS AND METHODS: We collected gene expression and clinicopathological data of 678 operated STS, and searched for correlations between the GGI-based classification and clinicopathological variables, including the metastasis-free survival (MFS). RESULTS: Based on GGI, 275 samples (41%) were classified as 'GGI-low' and 403 (59%) as 'GGI-high'. The 'GGI-high' class was more associated with poor-prognosis features than the 'GGI-low' class: pathological grade 3 (P = 9.50E-11), undifferentiated sarcomas and leiomyosarcomas (P < 1.00E-06), location in extremities (P < 1.00E-06), and complex genetic profile (P = 2.1E-20). The 5-year MFS was 53% (95%CI 47-59) in the 'GGI-high' class versus 78% (95%CI 72-85) in the 'GGI-low' class (P = 3.02E-11), with a corresponding hazard ratio for metastatic relapse equal to 2.92 (95%CI 2.10-4.07; P = 2.23E-10). In multivariate analysis, the GGI-based classification remained significant, whereas the pathological grade did not. In fact, the GGI-based classification stratified the patients with pathological grades 1 and 2 and those with pathological grade 3 in two classes with different 5-year MFS. Comparison of the GGI and CINSARC multigene signatures revealed similar correlations with clinicopathological variables, which were, however, stronger with GGI than with CINSARC, a strong concordance (71%) in terms of low-risk or high-risk classifications, and independent prognostic value for MFS in multivariate analysis, suggesting complementary prognostic information. CONCLUSION: GGI refines the prediction of MFS in operated STS and might improve the tailoring of adjuvant chemotherapy. Further clinical validation is warranted in larger retrospective, then prospective series, as well as the functional validation of relevant genes that could provide new therapeutic targets.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bertucci F, De Nonneville A, Finetti P, et al. The Genomic Grade Index predicts postoperative clinical outcome in patients with soft-tissue sarcoma. Ann Oncol. 2018. PMID: 29069276. doi:10.1093/annonc/mdx699

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。